Uniphar (DUB:UPR) Stock Based Compensation: €4 Mil (TTM As of Dec. 2025)


DUB:UPR Uniphar PLC DUB:UPR
81 GF Score
Price €4.82
GF Value €3.64
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Uniphar Stock Based Compensation?

Uniphar DUB:UPR +0.42% 81 Stock Based Compensation is €4 Mil as of Dec. 2025. GuruFocus rates DUB:UPR with a GF Score™ of 81/100 and a GF Value™ of €3.64 (Significantly Overvalued). The stock has 9 warning signs investors should review.

Uniphar's Stock Based Compensation for the six months ended in Dec. 2025 was €2 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was €4 Mil.

Uniphar Stock Based Compensation Related Terms

Uniphar Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Uniphar's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Uniphar Stock Based Compensation Chart

Uniphar Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.18 0.54 2.82 2.94 3.77

Uniphar Semi-Annual Data
Dec16 Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.34 1.47 1.47 1.88 1.88
DUB:UPR
81GF Score
Uniphar PLC DUB:UPR
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Uniphar Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €4 Mil.

What does a Stock Based Compensation of €4 Mil mean?
Uniphar (DUB:UPR) has a Stock Based Compensation of €4 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Uniphar and its competitors.
Is Uniphar's Stock Based Compensation too high?
Uniphar's current Stock Based Compensation is €4 Mil. Overall, Uniphar has a GF Score™ of 81/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Uniphar's Stock Based Compensation compare to MCK and CAH?
Uniphar's Stock Based Compensation of €4 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Medical Distribution company?
A good Stock Based Compensation depends on the Medical Distribution industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Uniphar and its competitors. Uniphar's current Stock Based Compensation is €4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Uniphar stock overvalued right now?
Based on GuruFocus' analysis, Uniphar (DUB:UPR) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.64, compared to a current price of €4.82 — trading 32.4% above its estimated fair value. The current Stock Based Compensation is €4 Mil. Uniphar's overall GF Score™ is 81/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Uniphar (DUB:UPR), the current Stock Based Compensation is €4 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Uniphar (DUB:UPR) Overvalued in 2026?

Based on GuruFocus' analysis, Uniphar stock appears to be overvalued. The current stock price of €4.82 is trading 32.4% above its estimated GF Value™ of €3.64. GuruFocus considers Uniphar to be Significantly Overvalued.

Key valuation signals for DUB:UPR:

  • Stock Based Compensation: €4 Mil
  • GF Value™: €3.64 vs. price of €4.82 (32.4% above fair value)
  • GF Score™: 81/100 with 9 warning signs

No single metric tells the full story. See the DUB:UPR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Uniphar Business Description

Other Exchanges UPR:UK0NR:Germany
Address 4045 Kingswood Road, Citywest Business Park, Dublin, IRL, D24 V06K
Uniphar PLC is a service provider within the pharmaceutical and healthcare sector. The company is an international diversified healthcare services business servicing the requirements of multinational pharmaceutical and medical technology manufacturers across three divisions - Uniphar Pharma, Uniphar Medtech and Uniphar Supply Chain & Retail. Uniphar Pharma enables pharma and biotech companies to bring medicines to markets globally and provide healthcare professionals with access to medicines that can't be sourced through traditional channels. Uniphar Medtech is a Pan-European medical device distributor and solutions partner. Uniphar Supply Chain & Retail is the pharmaceutical wholesaler in Ireland offering of retail pharmacies.
81GF Score

Get the complete analysis for DUB:UPR

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.82
Price
€3.64
GF Value